Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "Library",
"id" : "179632",
"meta" : {
"versionId" : "4",
"lastUpdated" : "2023-12-15T13:02:51.862Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"
]
},
"language" : "en",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <table class=\"narrative-table\">\n <tbody>\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">Metadata</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Version</th>\n\n\n\n<td class=\"content-container\">1.0.0-ballot3</td>\n\n\n</tr>\n\n\n\n\n\n\n\n \n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Identifier</th>\n\n\n\n<td class=\"content-container\">179632</td>\n\n\n</tr>\n\n\n \n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Identifier</th>\n\n\n\n<td class=\"content-container\">urn:oid:2.16.840.1.113883.4.642.40.44.28.2</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Subject Type</th>\n\n\n\n<td class=\"content-container\"><a href=\"Group-179619.html\">SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</a></td>\n\n\n</tr>\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Use Context</th>\n\n\n\n<td class=\"content-container\">\n Evidence Communication\n\n = \n SystematicReviewExcludedStudies\n\n\n</td>\n\n\n</tr>\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Jurisdiction</th>\n\n\n\n<td class=\"content-container\">\n World\n\n\n</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Steward (Publisher)</th>\n\n\n\n<td class=\"content-container\">HL7 International / Clinical Decision Support</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Steward Contact</th>\n\n\n\n<td class=\"content-container\">HL7 International / Clinical Decision Support</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Developer</th>\n\n\n\n<td class=\"content-container\">Brian S. Alper</td>\n\n\n</tr>\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Description</th>\n\n\n\n<td class=\"content-container\"><div><p>11 excluded studies</p>\n</div></td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Copyright</th>\n\n\n\n<td class=\"content-container\"><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div></td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Type</th>\n\n\n\n<td class=\"content-container\">\n Asset Collection\n\n\n</td>\n\n\n</tr>\n\n\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n<tr>\n \n \n \n \n \n <td class=\"content-container\">\n \n \n \n \n \n \n \n </td>\n</tr>\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\"><a name=\"parameters\"> </a>Parameters</th>\n\n\n</tr>\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Parameter</th>\n\n\n\n<td class=\"content-container\">None</td>\n\n\n</tr>\n\n\n\n\n\n\n\n<tr>\n <th colspan=\"2\" scope=\"row\" class=\"row-header\">Generated using version 0.5.4 of the sample-content-ig Liquid templates</th>\n</tr>\n\n </tbody>\n </table>\n</div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Library/179632",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "179632",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44.28.2"
}
],
"version" : "1.0.0-ballot3",
"title" : "SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
"status" : "active",
"experimental" : false,
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/library-type",
"code" : "asset-collection",
"display" : "Asset Collection"
}
]
},
"subjectReference" : {
🔗 "reference" : "Group/179619",
"type" : "Group",
"display" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"
},
"date" : "2023-11-26T18:15:27.442Z",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"description" : "11 excluded studies",
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "SystematicReviewExcludedStudies",
"display" : "SystematicReviewExcludedStudies"
}
]
}
}
],
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001",
"display" : "World"
}
]
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"author" : [
{
"name" : "Brian S. Alper"
}
],
"relatedArtifact" : [
{
"type" : "derived-from",
"resourceReference" : {
🔗 "reference" : "Citation/179613",
"type" : "Citation",
"display" : "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Different comparison (ADT versus ADT plus estramustine)"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179628",
"type" : "Citation",
"display" : "14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Different comparison (ADT versus ADT plus chemotherapy without docetaxel)"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179631",
"type" : "Citation",
"display" : "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Different comparison (ADT versus ADT plus radiotherapy)"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179627",
"type" : "Citation",
"display" : "19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Different comparison (ADT versus ADT plus radiotherapy)"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179626",
"type" : "Citation",
"display" : "22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Different comparison (ADT versus ADT plus radiotherapy)"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179625",
"type" : "Citation",
"display" : "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Nonrandomized"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179629",
"type" : "Citation",
"display" : "23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Neoadjuvant treatment"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179624",
"type" : "Citation",
"display" : "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Nonrandomized"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179622",
"type" : "Citation",
"display" : "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "High-risk localized prostate cancer"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179621",
"type" : "Citation",
"display" : "26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Locally advanced or metastatic (without metastatic subgroup analysis)"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179630",
"type" : "Citation",
"display" : "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."
}
},
{
"type" : "contains",
"classifier" : [
{
"text" : "Nonrandomized"
}
],
"resourceReference" : {
🔗 "reference" : "Citation/179623",
"type" : "Citation",
"display" : "23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer."
}
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3.
Generated
2026-05-12
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change